# Author Index Volume 14 (2012)

Abraham, I. and J.L. Bootman, Why pharmacoeconomic policy should be transnational (1) 7–16

Abraham, I., see Olvey, E.L. (1) 27–35

Balbino, J.E., see de Labry Lima, A.O. (2-4) 187–193

Barletta, J.F., see Patanwala, A.E. (1) 93–104

Bootman, J.L. and G.H. Skrepnek, Achieving value: The role of pharmacoeconomics (1) 3–6

Bootman, J.L., see Abraham, I. (1) 7–16

Bootman, J.L., see Olvey, E.L. (1) 69–81

Cabezas, M.D., Current trend in pharmaceutical law in EU (2-4) 195–207

Cheng, W., Y. Fang, D. Fan, J. Sun, X. Shi and J. Li, Study on the effect of “zero mark-up” policy on medicines in Beijing community health facilities (2-4) 177–186

Chowdhury, N., Limits to the legal deliberation of science questions: A case study of borderline medical products in Europe (2-4) 157–175

Cordoba-Diaz, D., see Quezada, M.S. (2-4) 223–228

del Castillo Rodriguez, C., see Quezada, M.S. (2-4) 223–228

Erstad, B.L., see Patanwala, A.E. (1) 93–104

Fan, D., see Cheng, W. (2-4) 177–186

Fang, Y., see Cheng, W. (2-4) 177–186

Fishman, J.C. and G.H. Skrepnek, Pharmacoeconomic analyses of treatments for rare disease (1) 51–67

Forns, J.R., see de Labry Lima, A.O. (2-4) 187–193

Li, J., see Cheng, W. (2-4) 177–186

MacDonald, K., see Olvey, E.L. (1) 27–35

Mutebi, A., Patient-reported outcomes in the post-approval environment: Opportunities and challenges (1) 83–91

1389-2827/12/$27.50 © 2012 – Network of Centres for Study of Pharmaceutical Law. All rights reserved
Nevins, R., see Skrepnek, G.H. (1) 37– 49

Olvey, E.L. and J.L. Bootman, The ‘fourth hurdle’ of pharmacogenomics (1) 69– 81

Olvey, E.L., K. MacDonald and I. Abraham, Comparative effectiveness research: The translational science of comparing the what, how, when, in whom, by whom, and why of treatment effectiveness (1) 27– 35

Olvey, E.L., see Skrepnek, G.H. (1) 105–122

Palchik, V., see Real, J.P. (2-4) 209–222

Palma, S.D., see Real, J.P. (2-4) 209–222

Patanwala, A.E., J.F. Barletta and B.L. Erstad, Pharmacoepidemiology and patient safety in the critically ill (1) 93–104

Quezada, M.S., C. del Castillo Rodríguez and D. Cordoba-Díaz, Pharmacist’s role in the studies of the veterinary-medicines-residues depletion (2-4) 223–228


Sahai, A., see Skrepnek, G.H. (1) 105–122

Salamano, M., see Real, J.P. (2-4) 209–222

Shi, X., see Cheng, W. (2-4) 177–186

Skrepnek, G.H., E.L. Olvey and A. Sahai, Econometric approaches in evaluating costs and outcomes within pharmacoeconomic analyses (1) 105–122

Skrepnek, G.H., R. Nevins and S. Sullivan, An assessment of health and work productivity measurement in employer settings (1) 37– 49

Skrepnek, G.H., see Bootman, J.L. (1) 3– 6

Skrepnek, G.H., see Fishman, J.C. (1) 51– 67

Skrepnek, G.H., see Villa, L.A. (1) 17– 25

Sullivan, S., see Skrepnek, G.H. (1) 37– 49

Sun, J., see Cheng, W. (2-4) 177–186

Traverso, M.L., see Real, J.P. (2-4) 209–222

Valverde, J.L., Corporate responsibility and pharmaceutical fraud (2-4) 129–156

Villa, L.A. and G.H. Skrepnek, Pharmacoeconomics and developing nations (1) 17– 25